Cargando…

Serum Levels of TNF-α, IFN-γ, IL-6, IL-8, IL-12, IL-17, and IL-18 in Patients With Active Psoriasis and Correlation With Disease Severity

Recent progress in the understanding of psoriasis has shown that the regulation of local and systemic cytokines plays an important role in its pathogenesis. The most often used psoriasis score is the psoriasis area and severity index (PASI). A simple laboratory test from a blood sample would be an a...

Descripción completa

Detalles Bibliográficos
Autores principales: Arican, Ozer, Aral, Murat, Sasmaz, Sezai, Ciragil, Pinar
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2005
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1533889/
https://www.ncbi.nlm.nih.gov/pubmed/16258194
http://dx.doi.org/10.1155/MI.2005.273
_version_ 1782129078351953920
author Arican, Ozer
Aral, Murat
Sasmaz, Sezai
Ciragil, Pinar
author_facet Arican, Ozer
Aral, Murat
Sasmaz, Sezai
Ciragil, Pinar
author_sort Arican, Ozer
collection PubMed
description Recent progress in the understanding of psoriasis has shown that the regulation of local and systemic cytokines plays an important role in its pathogenesis. The most often used psoriasis score is the psoriasis area and severity index (PASI). A simple laboratory test from a blood sample would be an attractive, patient-independent, and observer-independent marker of disease severity. To this end, we evaluated the association of serum levels of some proinflammatory cytokines in vivo and their correlation with severity of psoriasis. The serum levels of cytokines levels were determined with the use of the ELISA method. All mean values except IL-17 levels of patients were significantly higher than those of controls. There was a significant correlation between serum levels of IFN-γ, IL-12, IL-17, and IL-18, and severity of the disease. Psoriasis can be described as a T-cell-mediated disease, with a complex role for a variety of cytokines, which has led to the development of new immunomodulatory therapies. In this study, serum TNF-α, IFN-γ, IL-6, IL-8, IL-12, and IL-18 levels were significantly higher in active psoriatic patients than in controls. Furthermore, high levels of IFN-γ, IL-12, and IL-18 correlated with the clinical severity and activity of psoriasis, and those measurements of serum levels of these cytokines may be objective parameters for the disease severity.
format Text
id pubmed-1533889
institution National Center for Biotechnology Information
language English
publishDate 2005
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-15338892006-08-21 Serum Levels of TNF-α, IFN-γ, IL-6, IL-8, IL-12, IL-17, and IL-18 in Patients With Active Psoriasis and Correlation With Disease Severity Arican, Ozer Aral, Murat Sasmaz, Sezai Ciragil, Pinar Mediators Inflamm Research Communication Recent progress in the understanding of psoriasis has shown that the regulation of local and systemic cytokines plays an important role in its pathogenesis. The most often used psoriasis score is the psoriasis area and severity index (PASI). A simple laboratory test from a blood sample would be an attractive, patient-independent, and observer-independent marker of disease severity. To this end, we evaluated the association of serum levels of some proinflammatory cytokines in vivo and their correlation with severity of psoriasis. The serum levels of cytokines levels were determined with the use of the ELISA method. All mean values except IL-17 levels of patients were significantly higher than those of controls. There was a significant correlation between serum levels of IFN-γ, IL-12, IL-17, and IL-18, and severity of the disease. Psoriasis can be described as a T-cell-mediated disease, with a complex role for a variety of cytokines, which has led to the development of new immunomodulatory therapies. In this study, serum TNF-α, IFN-γ, IL-6, IL-8, IL-12, and IL-18 levels were significantly higher in active psoriatic patients than in controls. Furthermore, high levels of IFN-γ, IL-12, and IL-18 correlated with the clinical severity and activity of psoriasis, and those measurements of serum levels of these cytokines may be objective parameters for the disease severity. Hindawi Publishing Corporation 2005-10-24 /pmc/articles/PMC1533889/ /pubmed/16258194 http://dx.doi.org/10.1155/MI.2005.273 Text en Hindawi Publishing Corporation
spellingShingle Research Communication
Arican, Ozer
Aral, Murat
Sasmaz, Sezai
Ciragil, Pinar
Serum Levels of TNF-α, IFN-γ, IL-6, IL-8, IL-12, IL-17, and IL-18 in Patients With Active Psoriasis and Correlation With Disease Severity
title Serum Levels of TNF-α, IFN-γ, IL-6, IL-8, IL-12, IL-17, and IL-18 in Patients With Active Psoriasis and Correlation With Disease Severity
title_full Serum Levels of TNF-α, IFN-γ, IL-6, IL-8, IL-12, IL-17, and IL-18 in Patients With Active Psoriasis and Correlation With Disease Severity
title_fullStr Serum Levels of TNF-α, IFN-γ, IL-6, IL-8, IL-12, IL-17, and IL-18 in Patients With Active Psoriasis and Correlation With Disease Severity
title_full_unstemmed Serum Levels of TNF-α, IFN-γ, IL-6, IL-8, IL-12, IL-17, and IL-18 in Patients With Active Psoriasis and Correlation With Disease Severity
title_short Serum Levels of TNF-α, IFN-γ, IL-6, IL-8, IL-12, IL-17, and IL-18 in Patients With Active Psoriasis and Correlation With Disease Severity
title_sort serum levels of tnf-α, ifn-γ, il-6, il-8, il-12, il-17, and il-18 in patients with active psoriasis and correlation with disease severity
topic Research Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1533889/
https://www.ncbi.nlm.nih.gov/pubmed/16258194
http://dx.doi.org/10.1155/MI.2005.273
work_keys_str_mv AT aricanozer serumlevelsoftnfaifngil6il8il12il17andil18inpatientswithactivepsoriasisandcorrelationwithdiseaseseverity
AT aralmurat serumlevelsoftnfaifngil6il8il12il17andil18inpatientswithactivepsoriasisandcorrelationwithdiseaseseverity
AT sasmazsezai serumlevelsoftnfaifngil6il8il12il17andil18inpatientswithactivepsoriasisandcorrelationwithdiseaseseverity
AT ciragilpinar serumlevelsoftnfaifngil6il8il12il17andil18inpatientswithactivepsoriasisandcorrelationwithdiseaseseverity